DSP30
Based on 1 Customer Validation
DSP30 is a phosphorothioate cpG-oligodeoxynucleotide and a TLR9 agonist. DSP30 can activate immune system cells, including B cells and dendritic cells, by inducing proliferation and cytokine production.DSP30 can enhance the immunosuppressive function of bone marrow-multipotent mesenchymal stromal cells (BM-MSC). DSP30 combined with interleukin 2 (IL2) is an effective mitotic stimulant in B-cell disorders. DSP30 can be used for the genetic characteristic research and analysis of chronic lymphocytic leukemia (CLL).
For research use only. We do not sell to patients.
- Purity : 95.27%
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
Description
In Vitro
DSP30 (1 μM, 5 days) enhances the immunosuppressive function of BM-MSCs by promoting their proliferation, upregulating anti-inflammatory factors such as TGF-β1, maintaining high expression of IFN-γ and IL-10 in co-cultured T cells, and increasing the level of adenosine[1].
DSP30 (10 μg/mL, 5 days) enables CRTH2+ allergen-stimulated TH2 cells to produce IFN-γ[4].
DSP30 (0.1-1 μM, 0-72 h) significantly upregulates the expression of CD25 in B-CLL cells[5].
DSP30 (0.01-1 μM, 48-120 h) significantly enhances the killing effect of LMB-2 on B-CLL cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:BM-MSC, T lymphocytes
-
Concentration:1 μM
-
Incubation Time:5 days
-
Result:Had no impact on the expression of the inflammatory cytokine IL-6.
Induced the expression of IL-1β, IL-8 and TGF-β1.
Led to a significant increase in IL-8 and VCAM expression levels with LSP (HY-D1056) stimulation.
Maintained the high expression of IFN-γ and IL-10 in T cells with upregulated BM-MSC.
-
Cell Line:B-CLL cells
-
Concentration:1 μM
-
Incubation Time:5 days
-
Result:Significantly enhanced the sensitivity of B-CLL cells to LMB-2.
Enabled the originally drug-resistant B-CLL cells to reach the clinically achievable IC50 level.
Chemical Information
-
Appearance Solid
-
Color White to off-white
-
SMILES
N/A
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Protocols
-
MSC isolation and adherent expansion
Mesenchymal stromal/stem cells are isolated by their ability to adhere to tissue-culture plastic, expand as fibroblast-like colonies, and retain defined MSC identity after expansion; the accepted identity readout is plastic adherence, expression of CD105/CD73/CD90, absence of major hematopoietic markers including CD45/CD34/CD14 or CD11b/CD79α or CD19/HLA-DR, and in-vitro osteogenic, adipogenic, and chondrogenic differentiation.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Monocyte-derived dendritic cell differentiation
Human monocyte-derived dendritic cells are generated by isolating PBMC-derived monocytes and culturing them with GM-CSF plus IL-4, which produces cells with dendritic-cell antigen-presenting properties, reduced monocyte phenotype, and increased dendritic-cell functional readouts such as antigen uptake, allogeneic T-cell stimulation, and expression of markers including HLA-DR, CD80, CD86, CD83, CD1a, or CD209 depending on protocol and maturation state. The main readout is phenotypic and functional differentiation: immature MoDCs are commonly evaluated by loss or reduction of CD14 with acquisition of dendritic-cell markers and antigen uptake capacity, whereas mature MoDCs are evaluated by increased CD83, CD80, CD86, HLA-DR, and T-cell stimulatory function after exposure to maturation stimuli such as TNF-α or a cytokine/PGE2 cocktail.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2242 KB)
References
[1]. Sangiorgi B, et al. DSP30 enhances the immunosuppressive properties of mesenchymal stromal cells and protects their suppressive potential from lipopolysaccharide effects: A potential role of adenosine. Cytotherapy. 2016 Jul;18(7):846-59. [Content Brief]
[2]. Dun KA, et al. DSP30 and interleukin-2 as a mitotic stimulant in B-cell disorders including those with a low disease burden. Genes Chromosomes Cancer. 2018 May;57(5):260-267. [Content Brief]
[3]. Haferlach C, et al. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia. 2007 Dec;21(12):2442-51. [Content Brief]
[4]. Annunziato F, et al. Reversal of human allergen-specific CRTH2+ T(H)2 cells by IL-12 or the PS-DSP30 oligodeoxynucleotide. J Allergy Clin Immunol. 2001 Nov;108(5):815-21. [Content Brief]
[5]. Decker T, et al. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood. 2002 Feb 15;99(4):1320-6. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)